BlackRock Greater Europe Investment Trust Plc – Portfolio Update

The information contained in this release was correct as at 28 February 2026.
Information on the Company’s up to date net asset values can be found on the
London Stock Exchange website at:

https://www.londonstockexchange.com/exchange/news/market-news/market-news
-home.html.

BLACKROCK GREATER EUROPE INVESTMENT TRUST PLC (LEI – 5493003R8FJ6I76ZUW55)

All information is at 28 February 2026 and unaudited.
Performance at month end with net income reinvested

One Three One Three Launch

Month Months Year Years (20 Sep 04)

Net asset value (undiluted) 2.8% 5.1% 0.6% 19.9% 803.9%
Share price 3.2% 6.1% 2.8% 20.1% 772.2%
FTSE World Europe ex UK 4.7% 10.2% 24.3% 52.1% 629.7%

Sources: BlackRock and Datastream

At month end

Net asset value (capital only): 633.94p
Net asset value (including income): 635.71p
Share price: 605.00p
Discount to NAV (including income): 4.8%
Net gearing: 2.9%
Net yield1: 1.2%
Total assets (including income): £586.9m
Ordinary shares in issue2: 92,321,027
Ongoing charges3: 0.95%

1  Based on an interim dividend of 1.75p per share and a final dividend of 5.40p
per share for the year ended 31 August 2025.

2  Excluding 25,607,911 shares held in treasury.
3  The Company’s ongoing charges are calculated as a percentage of average daily
net assets and using the management fee and all other operating expenses
excluding finance costs, direct transaction costs, custody transaction charges,
VAT recovered, taxation, write back of prior year expenses and certain non
-recurring items for the year ended 31 August 2025.

Sector Analysis Country Analysis Total Assets (%)
Total Assets (%) France 26.3
Industrials Netherlands 15.9
41.9 Switzerland 14.3
Financials Ireland 6.8
17.9 Germany 6.7
Technology Spain 5.7
16.9 Finland 4.1
Consumer Belgium 3.7
Discretionary 14.1 United States 3.3
Health Care Sweden 3.2
6.8 Norway 3.1
Basic Materials Italy 2.8
3.3 United Kingdom 2.8
Utilities Austria 2.1
2.0 Denmark 2.1
Net Current Net Current Liabilities -2.9
Liabilities -2.9 —–
100.0
—– =====

100.0

=====

Top 10 holdings Country Fund %
ASML Netherlands 6.2
Safran France 5.8
Schneider Electric France 5.0
Compagnie Financiere Richemont Switzerland 4.7
BE Semiconductor Netherlands 4.3
Kone Finland 4.0
Belimo Switzerland 4.0
MTU Aero Engines Germany 3.9
Lonza Group Switzerland 3.8
KBC Groep Belgium 3.6

Commenting on the markets, Stefan Gries and Brian Hall, representing the
Investment Manager noted:

During the month, the Company’s NAV rose +2.8% and the share price rose +3.2%.
For reference, the FTSE Europe ex UK market returned +4.7% during the period.

Results season continued in February, arguably with European earnings doing
slightly better than expected. However, earnings results mattered little to a
market that continues to be focused on narratives such as AI disruption. For the
most part, moves previously taken to reduce the portfolio’s exposure (e.g.
shifting software to semiconductors) meant we were on the right side of the AI
tech trade. However, a broader AI disruption trade aiming to buy AI-proof
assets, called the HALO trade (Heavy Asset, Low Obsolesce), drove market gains
in unlikely areas for the current environment – businesses highly levered to
demand outperforming such as telcos, food and beverage, and energy. European
banks also came under pressure in the month as momentum unwound and the industry
took its turn in the AI disruption crosshairs. The latter was focused both on
new AI tools that are seen as having potential to disrupt deposit businesses as
well as the broader macro implications of wide-spread job losses being
hypothesised.

Sector allocation effects were negative in February driven by underweight
positioning to Consumer Staples and those sectors favoured by the move to `heavy
assets’ deemed AI-proof such as Telcos, Energy and Utilities.

The portfolio’s position in ChemoMetec detracted on weak results that were
driven in part by the US government shut down but also by a previously flagged
slowdown in instruments given the time it takes for customers to validate new
product. Full year guidance was reiterated though this will require a big step
up from H1. Longer-term, a new deal signed with Roche appears to be a massive
opportunity – one which the market does not know how to value yet – while
consolidation going from 3 to 2 players will benefit the growth trajectory over
the next 5 years.

Adyen detracted with shares down after a disappointing update that saw 2026
revenue guidance cut. Previously guided for low to mid 20% growth – a target
just reiterated at their November CMD – the new guide fell to 20-22% with
management citing a deeper review of clients undertaken at the end of 2025 as
opposed to deterioration in underlying trends. Regardless, the market had no
appetite for downgrades against the backdrop of fear for AI disintermediation.

Despite posting extremely strong earnings, shares in Belimo fell over the month.
News of +23% FY25 organic sales growth had already been pre-released, but
additional details of margin expansion and a 36% ROCE (Return on Capital
Employed) were also impressive. It was the 2026 guidance which led to the
negative share price reaction, although mid-teens revenue growth and >20%
margins were broadly in line with consensus expectations. We are used to the
Belimo management team guiding conservatively and remain confident in the
company’s ability to execute so have used the pull back as an opportunity to add
to the position.

European banks detracted on the unwind of momentum and AI concerns as noted
above. However, banks reported solid results in the month, supportive of our
bottom-up investment theses. We do though remain aware of macro concerns in the
market and look for improving lending and deposit growth to disprove this
narrative.

MTU was a detractor as free cash flow conversion marginally disappointed as sell
-side analysts had not factored in the full extent of reinvestments being made
into future growth. We are happy with where these investments are being focused
and believe it supports the long-term prospects of the company.

Not holding Novo Nordisk was positive for relative returns as the latest
Cagrisema trial- a head-to-head against Eli Lilly’s Zepbound – failed to show
superiority. The result calls into question consensus’ $7.3b sales expectations
in 2032 and while they are talking about running more trials at higher doses,
there remains too much uncertainty.

BE Semiconductor added positive attribution on strong results and evidence they
are starting to see the legacy business improve from tightness in
semiconductors.

A holding in Kongsberg also moved higher driven by results which beat across all
lines after a weaker Q3 result. The market has also had time to digest plans to
split the marine business which was an overhang on shares after the announcement
last year.

Safran was a positive contributor as their earnings release showed strong and
sustained trends in the aftermarket business, while the new engine pipeline also
looked solid. Cash flow in particular came in better than expected, with 2024
-2028 cumulative guide above the previous guide and consensus expectations. A
2026 EBIT (Earnings Before Interest and Taxes) guidance ahead of expectations so
early in the year was a confident move from the management team. This implies
aftermarket assumptions ahead of consensus expectations and is a positive read
across for other civil aerospace holdings in the portfolio.

Outlook

The macro backdrop continues to tread along without major concern. There has
been more mixed data out of the US with GDP below estimates but this was largely
explained by the government shut down in the back of 2025 and is expected to
recover. Unemployment and non-farm payrolls have also shown some volatility
month to month but there’s been nothing alarming on balance and we should expect
to see this in the US given the higher adoption rate of AI compared to other
countries. In Europe, Germany, Spain and France are all seeing improvement.
However, geopolitics remain a wild card here as a prolonged conflict in Iran
could have inflationary impacts from oil and gas prices.

Despite the market volatility, we remain optimistic given the underlying macro
backdrop. Nothing we are seeing in the industrial or consumer economy makes us
want to panic buy defensive assets for the sake of hiding. We have been
pragmatic with our focus on being on the right side of disruption and earnings.
We continue to see a resilient bottom-up picture which should support a change
in market drivers in time once uncertainties clear, adding breadth to what has
been a very narrowly driven market.

Europe remains home to many world-class franchises, companies owning core
technologies that make them the enablers of some of the large transformational
changes going on around us. We aim to align shareholder capital to those
businesses that are exposed to large and enduring spending streams. Overall, we
retain our core exposure to companies with predictable business models, higher
than average returns on capital, strong cash flow conversions and opportunities
to reinvest that cash flow into future growth projects at high incremental
returns.

19 March 2026

ENDS

Latest information is available by typing www.blackrock.com/uk/brge on the
internet, «BLRKINDEX» on Reuters, «BLRK» on Bloomberg or «8800» on Topic 3 (ICV
terminal).  Neither the contents of the Manager’s website nor the contents of
any website accessible from hyperlinks on the Manager’s website (or any other
website) is incorporated into, or forms part of, this announcement.

This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/22396/4323906/3994042.pdf Release